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 2 
ABSTRACT 27 
Context and Objective: This study aimed to comprehensively assess the macro- and microcirculation of 28 
severely obese adolescents (SOA) and normal-weight counterparts, and determine the longitudinal effects 29 
of weight loss on vascular function in SOA. 30 
Design, Setting, Participants, and Outcome Measures:  Seventeen SOA (BMI z-score = 4.22 ± 0.73) 31 
before and after a 4-month weight loss program, and nineteen puberty-matched normal-weight 32 
counterparts (BMI z-score = -0.02 ± 1.04) were studied. Brachial artery flow-mediated dilation (FMD) 33 
and response to sublingual nitrate (NMD) were assessed by high-resolution ultrasound. Microvascular 34 
reactivity was evaluated by laser Doppler flowmetry in response to NMD, iontophoresis of acetylcholine 35 
(ACh) and sodium nitroprusside (SNP), and local hyperthermia. Plasma insulin, leptin, resistin, C-36 
reactive protein, myeloperoxidase (MPO), and tissue plasminogen activator (tPA) were measured. 37 
Results: At baseline, SOA had similar FMD and impaired NMD in the brachial artery compared to 38 
normal-weight adolescents. Similarly, peak responses to ACh and SNP iontophoresis and to local 39 
hyperthermia were unaltered whereas cutaneous blood flow following NMD was lower in the forearm 40 
microcirculation of SOA. All plasma measurements were significantly higher in SOA. After the program, 41 
SOA presented a weight reduction of 7.4 ± 3.1 %, but neither brachial artery nor microvascular reactivity 42 
variables were improved. Significant decreases were detected in plasma leptin, MPO and tPA. 43 
Conclusions: Macro- and microvascular endothelial function are preserved in adolescents with severe 44 
obesity. Conversely, a 7 % weight loss does not improve their impaired smooth muscle response to 45 
exogenous organic nitrate in both vascular beds, despite reducing plasma markers adversely related to 46 
vascular homeostasis. 47 
 48 
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 Severe obesity in pediatric population is a major public health concern, as well as one of the fastest 49 
growing obesity categories in childhood obesity (1), which is associated with vascular risk factors and 50 
disease in adulthood (2). Moreover, the progressive exacerbation of preclinical signs of vascular disease 51 
might be particularly accelerated in obese adolescents on account of the pro-inflammatory and pro-52 
oxidative changes that occur during puberty, plausibly hampering vascular function (3). The early 53 
detection of vascular alterations is thus a major clinical goal to identify subjects at risk for cardiovascular 54 
morbidity, and to initiate strategies to reduce risk exposure.  55 
 56 
Endothelial dysfunction is a primary sign of the early stage of atherosclerotic disease, appearing long 57 
before the symptoms (4). This alteration has been observed at the macrovascular level in severely obese 58 
children and adolescents (5). However, data remain scarce concerning the endothelial function at the 59 
microcirculation level in severe childhood obesity (6). The microcirculation, in turn, is increasingly 60 
recognized to be independently involved in vascular diseases previously thought to be primarily a 61 
macrocirculation matter (7). Furthermore, the specific vascular profile of severely obese pubertal 62 
adolescents (SOA) is unknown, since the aforementioned studies included pre-pubertal children (5; 6).  63 
 64 
Although lifestyle interventions, including physical activity and/or diet, result in well-known vascular 65 
benefits associated with a decrease in markers of inflammation and oxidative stress in moderately obese 66 
children and adolescents (3), their effects remain unknown in severe childhood obesity. Therefore, the 67 
aims of the present study were 1) to investigate, in a comprehensive manner, the vascular function in the 68 
macro- and microcirculation of severely obese and normal weight adolescents, and 2) to determine the 69 
longitudinal effects of a weight loss program on both vascular beds in SOA. 70 
 71 
MATERIALS AND METHODS  72 
 73 
Subjects 74 
 4 
Seventeen adolescents with severe obesity were recruited from a pediatric weight management center. 75 
Obesity was defined according to the age and sex-specific cut-off points of childhood obesity as indicated 76 
by the International Obesity Task Force (8). BMI z-scores were calculated and values greater than 3 77 
defined severe obesity (9). Nineteen healthy normal-weight pubertal stage-matched adolescents were 78 
recruited from the community to serve as controls (Table 1). All subjects were normotensive (defined as a 79 
pressure < 95th sex-, age-, and height-specific percentiles), non-diabetic, and free from further known 80 
obesity-related comorbidities. Exclusion criteria for all subjects included a family history of premature 81 
cardiovascular disease, intake of any medication, pubertal status assessed by Tanner stage < 2, weight 82 
loss larger than 5% of their total weight during the previous 3 months, and non-sedentary status ( > 3 h of 83 
exercise per week) to minimize training effects. Informed consent was obtained from the parents and 84 
adolescents. The study protocol was approved by the local Ethics Committee and performed in 85 
accordance with the principles outlined in the Declaration of Helsinki. 86 
 87 
Weight loss program 88 
The SOA group underwent a weight loss program consisting in diet and exercise managed by the 89 
pediatric weight center. Clinical and vascular assessment of SOA was performed within the first week, 90 
and four months later after inclusion in the center. A 4-month period between assessments was considered 91 
sufficient time to detect successful weight loss (estimated at 7% of the initial weight) and potential 92 
vascular improvement in obese subjects (10). SOA received a moderately hypocaloric diet (reduction of 93 
~300 to 500 calories/day) based on a balanced distribution of carbohydrates (55%), proteins (15%), and 94 
lipids (30% total, with less than 10% saturated fat), while performing a physical activity program 95 
consisting of four 90-minute supervised sessions per week. Each session mostly involved aerobic 96 
exercise, including dancing, tennis, and recreational games, intended to encourage physical activity in the 97 
subjects. 98 
 99 
Vascular measurements 100 
 5 
All vascular measurements were performed after fasting overnight in a quiet room with a controlled 101 
temperature between 22 and 24 ºC. All subjects had abstained from strenuous exercise for 48 h before the 102 
test. Measurements commenced after 20 minutes of acclimatization in supine position, and blood 103 
pressures were measured on the left arm by an automated system (Dinamap, GE Medical Systems, 104 
Milwaukee, USA). 105 
Macrovascular assessment of the brachial conduit artery was performed by the same investigator (A.V.), 106 
according to the International Brachial Reactivity Task Force Guidelines (11). Brachial measurements 107 
were achieved using high-resolution vascular ultrasonography (MyLab30, Esaote SpA, Firenze, Italy), 108 
with a 10-MHz multi-frequency linear probe. B-mode images and Doppler signals were continuously and 109 
simultaneously recorded for off-line analysis. All results were calculated as the average of 5 consecutive 110 
measurements. Flow mediated dilation (FMD), a well-established noninvasive method to estimate 111 
endothelial function in conduit artery, was performed. Briefly, a pneumatic cuff was put on the right 112 
forearm near the elbow. The ultrasound probe was placed approximately midway between the antecubital 113 
and axillary regions, and baseline brachial artery diastolic lumen diameter was measured. The cuff was 114 
then inflated to 250 Hg mm for 5 minutes before sudden cuff deflation induced post-ischemic hyperemia. 115 
Fifteen minutes later, baseline measurements were repeated before 0.4 mg of isosorbide dinitrate (Isocard, 116 
Schwarz Pharma, Monheim, Germany), an endothelium-independent vasodilator, was given sublingually 117 
to assess endothelium-independent vasodilation (nitrate-mediated dilation, NMD) . This procedure is 118 
described in detail elsewhere (12). FMD and NMD were expressed as the percentage change of peak 119 
diastolic brachial diameter after reactive hyperemia and exogenous organic nitrate administration, 120 
respectively, relative to the baseline diastolic diameter. Time-averaged mean blood flow velocity and 121 
blood flow were determined, as previously described (13). Shear rate (s-1) was calculated as 4 × time-122 
averaged mean blood flow velocity/mean brachial diameter, to estimate resting and peak shear stress (14). 123 
FMD was normalized by the net shear rate stimulus (peak minus resting shear rate, ∆shear rate). Although 124 
the validity of shear normalization is controversial, we added this measurement as it is commonly used by 125 
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other researchers. Within-subject coefficient of variations in our laboratory at rest were 1.8% for arterial 126 
diameters, 13.2% for time averaged mean velocity and 12.7% for blood flow (13). 127 
 128 
Microvascular assessment of cutaneous blood flow (CBF) was performed by one investigator (D.M.) by 129 
means of the laser Doppler flowmetry (LDF) technique. LDF continuously monitors perfusion by 130 
measuring microvascular red blood flow using the Doppler principle. The LDF technique has been 131 
previously described in detail (15). Cutaneous blood flow (CBF) was measured in conventional perfusion 132 
units (PU) using a LDF system (Periflux PF 5000, Perimed, Stockholm, Sweden), equipped with a 133 
thermostatic LDF probe with an effective surface of 0.95 cm2 (PF 481, Perimed, Stockholm, Sweden), on 134 
the volar surface of the left forearm. Before commencing the iontophoresis protocol, resting forearm CBF 135 
was calculated by averaging a 3-minute steady recording using a non-drug-containing LDF probe. A 136 
direct current for drug iontophoresis was provided by a battery-powered current stimulator (Perilont, 137 
Perimed, Stockholm, Sweden). Iontophoresis allows non-invasive drug delivery to the skin without 138 
systemic effects and perturbation of the skin. Microvascular responses to iontophoresis of acetylcholine 139 
(ACh) and sodium nitroprusside (SNP) were assessed. SNP 1% and ACh 1% solutions, adjusted to a 140 
physiological ionic strength (0.154 M) by adding saline solution, were administered via two drug delivery 141 
electrodes, each inserted within an LDF probe, positioned 10 cm apart avoiding superficial veins and 142 
broken epidermal areas. In order to minimize non-specific vasodilatory effects, the iontophoresis protocol 143 
consisted in a single anodal (ACh) or cathodal (SNP) pulse of 0.021 mA/cm2 for 370 s, yielding a total 144 
charge of 7.8 mC/cm2 (16). In addition, a non-drug containing LDF probe determined the CBF response 145 
to sublingual administration of organic nitrate (NMD). LDF probes were maintained at a constant 146 
temperature of 33ºC throughout the whole measuring process. To assess the local hyperthermia response, 147 
a non-drug containing LDF probe was heated to 42ºC for 5 minutes. Only the plateau phase 148 
(endothelium-dependent) of the hyperthermia response was analyzed. Peak CBF responses to ACh, SNP, 149 
NMD and local hyperthermia were determined as the maximum average value over a 10 s period within 150 
their respective procedures. Concerning the spatial variability of LDF measurements, the specific volar 151 
 7 
forearm location of each LDF probe and electrode was approximately maintained in all subjects, 152 
especially for SOA before and after the weight loss program in which locations were noted in relation to 153 
anatomical landmarks.  154 
 155 
Blood analysis 156 
Blood samples were collected after fasting overnight. Biochemical markers related to vascular function 157 
such as leptin, resistin, C-reactive protein (CRP), myeloperoxidase (MPO), and tissue plasminogen 158 
activator (tPA) were determined in plasma by bead-based multiplex immunoassays (FlowCytomix, 159 
eBioscience, San Diego, CA, USA). Plasma insulin was measured using the radioimmunoassay method 160 
(coat-a-count radioimmunoassay kit TKIN2, Siemens, Berlin, Germany).  161 
 162 
Statistical analysis 163 
All normally distributed variables were expressed as mean ± SD. Data that were not normally distributed 164 
(CRP, tPA, and microvascular variables) were log-transformed to approximate normality before 165 
parametric testing, and were expressed as median (interquartile range) in Tables 1 and 3. SOA versus 166 
normal-weight subjects were compared by independent t-tests and analysis of covariance (ANCOVA), 167 
including gender as a covariate. Paired student t-tests were used to assess SOA before and after the weight 168 
loss program. Bivariate associations between vascular and study variables were determined by calculating 169 
Pearson’s correlation coefficients. A two-tailed p-value less than 0.05 was considered significant. All 170 
statistical analyses were performed using MedCalc software (bvba, Mariakerke, Belgium). 171 
 172 
RESULTS 173 
 174 
The major clinical characteristics of the subjects are shown in Table 1. At baseline, SOA presented higher 175 
BMI, BMI z-score, and waist circumference than normal-weight adolescents. Likewise, SOA showed 176 
higher insulin, leptin, resistin, CRP, MPO, and tPA plasma levels (Table 1).  177 
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With respect to the vascular assessment in the brachial artery, similar FMD values were found between 178 
groups, whereas resting blood flow, resting shear rate, and peak shear rate were higher in SOA (Table 2). 179 
Normalization of FMD by ∆shear rate yielded similar values between groups. Conversely, SOA presented 180 
lower NMD of the brachial artery than normal-weight adolescents (Table 2).  181 
In the microcirculation, peak CBF during NMD was also reduced in SOA (Table 3). Resting CBF was 182 
lower in SOA, but peak CBF after ACh, SNP iontophoresis and local hyperthermia were unaltered 183 
between groups (Table 3). All previous results did not differ when adjusted for gender.  184 
Following correlation analysis (Table 4), ∆shear rate was positively associated with BMI (r = .372, P = 185 
.036), waist circumference (r = .366, P = .043), and tPA (r = .363, P = .045). Significant inverse 186 
associations were detected between NMD and adiposity measurements (weight, BMI, BMI z-score, and 187 
waist circumference), the strongest being for NMD and waist circumference (r = -.473, P = .006). 188 
Similarly, forearm resting CBF was inversely associated with adiposity measurements, and leptin (r = -189 
.447, P = .009). Negative associations were also detected for forearm peak CBF during NMD with 190 
resistin (r = -.528, P = .002), and MPO (r = -.381, P = .031) (Table 4). 191 
 192 
After the weight loss program, SOA exhibited a mean weight reduction of 7.4 ± 3.1 %, as well as 193 
decreased BMI, BMI z-score, and waist circumference (Table 1). Plasma leptin, MPO and tPA 194 
measurements were also significantly reduced in SOA (Table 1). As regards brachial artery variables, 195 
resting diameter was increased, while resting shear rate, peak shear rate and ∆shear rate were diminished 196 
(Table 2). No significant changes were observed in FMD or NMD (Table 2). Moreover, NMD remained 197 
impaired in SOA when adjusted for gender compared to normal-weight adolescents (P = .038). In the 198 
microcirculation, peak CBF during NMD was further reduced in SOA after the weight loss program, 199 
whereas no significant changes were noted in other microvascular variables (Table 3). 200 
 201 
DISCUSSION 202 
 203 
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The most important findings in this study are: 1) SOA exhibit preserved endothelial function but impaired 204 
smooth muscle response to exogenous organic nitrate in both macro- and microcirculation, and 2) a 4-205 
month weight-loss program does not improve NMD in either of the two vascular beds assessed in SOA, 206 
despite of a significant weight loss and decreased plasma levels of selective markers adversely related to 207 
vascular function. These findings add new evidence for endothelial function preservation in childhood 208 
obesity, which was proposed to be a transitory adaptation to chronic hyperemia. Nevertheless, the absence 209 
of improvement in NMD after a 7% weight loss suggests the necessity of longer and/or more intense 210 
weight loss programs in SOA.  211 
 212 
Although our finding of preserved FMD in SOA is not universal (5), the present study is in accordance 213 
with recent and larger published works comparing obese children and adolescents to their normal-weight 214 
counterparts (17-19). Since brachial blood flow at rest and during hyperemia was higher in obese 215 
children, Charakida et al. (19) hypothesized that the endothelial function of conduit arteries may be 216 
temporarily adapted to the hemodynamic consequences of adiposity, thus partially counteracting the well-217 
known adverse effects of obesity on vascular function. Likewise, we observed that SOA had increased 218 
both resting and hyperemic shear rate, which is the primary hemodynamic stimulus to induce endothelial 219 
nitric oxide synthase (eNOS) expression (20), probably increasing the endothelium-mediated vasodilatory 220 
capacity of SOA. Preserved endothelial function was also observed in the microcirculation via two 221 
different stimuli. Peak responses to iontophoresis of ACh and local hyperthermia in the forearm 222 
microcirculation were not attenuated in SOA. To our knowledge, no other studies have assessed the 223 
microvascular reactivity to ACh and/or local hyperthermia in obese adolescents without co-morbidities. 224 
Altogether, these findings support the hypothesis that during childhood there may be intervals in which 225 
obese children present a preserved endothelial function in both the macro- and microcirculation. Further 226 
research is needed to evaluate whether such intervals of adaptive compensatory endothelial function 227 
might imply a progressive or even more accelerated deterioration of vascular function during adulthood 228 
(21).  229 
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 230 
Unfortunately, previous reports indicating preserved endothelial function in obese children and 231 
adolescents (17-19) did not assess smooth muscle function, which is, apart from its intrinsic interest, 232 
recommended in order to confirm endothelial function results (11). Our results indicate that the smooth 233 
muscle response to exogenous organic nitrate (NMD) is impaired in the brachial artery and the 234 
microvasculature of SOA. This NMD impairment in conduit arteries was already described in obese 235 
children (22) and adolescents (5; 23; 24), but always in the presence of endothelial dysfunction (impaired 236 
FMD). Given that the FMD response includes at least in part the function of the smooth muscle, the 237 
unaltered FMD in SOA suggests that there is either normal smooth muscle function at submaximal 238 
vasodilation or impaired smooth muscle function at submaximal vasodilation counterbalanced by 239 
increased endothelial function, in line with the aforementioned hypothesis (19). Similarly, at 240 
microvascular level, endothelial responses (peak CBF after ACh iontophoresis and hyperthermia) were 241 
normal, however peak CBF following NMD was decreased in the forearm microcirculation of SOA. In 242 
contrast, a similar peak perfusion following SNP iontophoresis was detected in both groups. The reasons 243 
explaining the different results of these two nitrodilators are unclear. At first sight, considering that there 244 
is an increase of oxidative stress markers in the plasma of SOA, we might speculate that the orally 245 
administered organic nitrate (isorbide dinitrate, NMD) underwent a more prolonged exposure to oxidative 246 
stress-mediated inactivation than SNP, which was transdermally delivered. However, the fact that the 247 
dilator activity of organic nitrates depends on its conversion to nitric oxide (NO) inside the smooth 248 
muscle cells (25) weakens this hypothesis. Another potential explanation may be related to the 249 
vasodilatory effects inherently associated with the iontophoresis procedure (26). The electric current of 250 
iontophoresis could stimulate, to some extent, underlying mechanisms of vasodilation related to the so-251 
called axon reflex (27). Even though we tried to avoid non-specific effects of iontophoresis by reducing 252 
the current intensity, we cannot discard the possibility of some effects of SNP iontophoresis being 253 
attributed to the axon reflex response. Nevertheless, overall, these findings demonstrated for the first time 254 
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the proof of a widespread decreased smooth muscle function in SOA compared to normal-weight 255 
adolescents. 256 
 257 
Obesity and puberty, characterized by dynamic hormonal and physiological changes in boys and girls, 258 
may alter metabolic and vascular homeostasis by promoting a pro-inflammatory and pro-oxidant state (3). 259 
Effectively, plasma markers related to adiposity, inflammation, oxidative stress and endothelial activation 260 
were altered in SOA. At baseline, SOA presented elevated levels of insulin and leptin, two related 261 
hormones with overlapping effects on the hypothalamic control of energy homeostasis (28). Leptin is also 262 
associated with increased sympathetic activity (29), which was suggested to be compatible with the lower 263 
resting blood flow noticed in obese adults (30). Identically, SOA presented lower CBF at rest than 264 
normal-weight counterparts in relation to their higher leptin level (Table 4).  265 
In addition, SOA presented higher values of CRP and MPO, suggesting the presence of systemic 266 
inflammation (31) and neutrophil-mediated oxidative stress (32), respectively. In correlation analysis, 267 
MPO was inversely associated with NMD response in the microcirculation, but not in the brachial artery 268 
(Table 4), suggesting a higher vulnerability to oxidative stress-mediated inactivation of NO in the smaller 269 
vessels. Moreover, tPA, considered to reflect endothelial activation (33), was augmented in SOA and 270 
positively associated to ∆shear rate. Increased vascular shear stress was shown to stimulate tPA 271 
expression and secretion by endothelial cells (34), which may explain to some extent the higher plasma 272 
levels of tPA found in SOA. Regarding the prognostic significance of these markers, increases in plasma 273 
CRP and MPO were recently associated with cardiovascular risk in obese children (35), while high levels 274 
of tPA were found to precede the development of type 2 diabetes in a large longitudinal study (36).  275 
Furthermore, resistin was increased in SOA as well as negatively associated with peak NMD response in 276 
the microcirculation (Table 4). The latter finding could give new clues concerning the controversy on the 277 
role of resistin in the pathogenesis of obesity-related comorbidities (37). Otherwise, a 7 % weight loss did 278 
not modify the plasma levels of insulin, resistin and CRP in SOA. Nonetheless, the significant reductions 279 
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in leptin, MPO and tPA after weight loss reinforce the therapeutic effects of hypocaloric diets and 280 
physical activity programs in obese subjects.  281 
 282 
The success of the weight loss program in reducing adiposity and plasma markers potentially altering 283 
vascular homeostatis in SOA, did not involve beneficial effects on macro- and microvascular function. 284 
The impaired NMD in the brachial artery was not significantly enhanced in SOA. To our knowledge, only 285 
one prior study evaluated the effect of a non-pharmacological program in obese children presenting 286 
impaired NMD (38). Similarly, they reported no significant change in brachial NMD in a randomized 287 
controlled trial assessing the effects of 3-month of exercise training in obese children (38). However, that 288 
exercise strategy without dietary intervention did not result in any appreciable weight loss, whereas in our 289 
study SOA presented a 7 % weight loss, which was previously associated to vascular function 290 
improvement in obese subjects (10). One explanation for the lack of enhancement of brachial NMD in our 291 
study may be related to the elevated resting brachial shear rate, even after weight loss, observed in SOA. 292 
It is conceivable that chronic shear rate-stimulated overexpression of eNOS, thus increasing nitric oxide 293 
(NO) release, might lead to some degree of smooth muscle tolerance to NO-mediated vasodilation (39) 294 
that was not reversed by the 7% weight loss in SOA. Furthermore, the NMD response was further 295 
reduced in the microcirculation of SOA after weight loss. Currently, reasons for such decreased 296 
microvascular smooth muscle function are unclear and requires further investigation. Taken together, the 297 
outcomes of this study suggest that longer and/or more intense weight loss programs might be needed to 298 
restore smooth muscle function in the macro- and microcirculation of SOA.  299 
 300 
There are several limitations to the present study. This is a single-center study with limited sample size 301 
and conclusions must be taken with caution. Due to the nature of human research, there are likely to be 302 
unrecognized variables leading to residual confounding. For instance, despite the baseline assessment of 303 
SOA was performed within the first week after being admitted in the center, we cannot discard the 304 
possibility that some SOA anticipated a somewhat control of nutrient intake before their entrance in the 305 
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center, which might have positively influenced their baseline vascular responses. Furthermore, the 306 
cutaneous microcirculation, which we investigated, may raise doubts about its overall significance for 307 
vascular risk assessement. However, there is substantial evidence that cutaneous microcirculation is 308 
representative of the microcirculation in general. This is underscored by several reports indicating that 309 
cutaneous microvascular function mirrors generalized systemic microvascular function (40).  310 
 311 
In summary, we have shown that endothelial function is preserved in the macro- and microcirculation of 312 
adolescents with severe obesity. Nevertheless, a 7 % weight loss does not induce an improvement of their 313 
impaired smooth muscle response to organic nitrate in whichever vascular bed assessed. Further studies 314 
are required to determine whether longer and/or more intense weight loss programs can enhance arterial 315 
smooth muscle function in this population. 316 
 317 
 318 
 319 
 320 
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Table 1 Clinical characteristics and biochemical measurements of normal-weight and severely obese 421 
adolescents before and after a 4-month weight loss program 422 
SOA 
Characteristics Controls Before After 
Girls/boys 11/8 12/5 12/5 
Age (years) 15.09 ± 1.32 13.45 ± 1.18* 13.79 ± 1.18† ‡ 
Pubertal stage (Tanner) 3.50 ± 0.73 3.33 ± 1.13 ― 
Height (cm) 165.32 ± 9.05 162.71 ± 5.95 163.88 ± 6.18† 
Weight (kg) 53.14 ± 9.56 88.65 ± 15.62* 81.91 ± 13.69† ‡ 
BMI (kg/m2) 19.32 ± 2.32 33.36 ± 4.86* 30.43 ± 4.42† ‡ 
BMI z-score -0.02 ± 1.04 4.22 ± 0.73* 3.46 ± 0.68† ‡ 
Waist circumference (cm) 68.05 ± 7.32 109.50 ± 14.32* 101.25 ± 13.83† ‡ 
Heart rate (beats/min) 65.52 ± 10.75 65.50 ± 9.80 63.41 ± 9.74 
SBP (mm Hg) 102.84 ± 8.69 98.41 ± 9.44 101.53 ± 7.84 
DBP (mm Hg) 60.05 ± 6.72 57.06 ± 6.47 56.24 ± 8.45 
Insulin (µU/mL) 3.32 ± 1.47 6.15 ± 4.88* 5.04 ± 2.86‡ 
Leptin (ng/mL) 17.29 ± 15.41 47.56 ± 27.18* 38.38 ± 21.08† ‡ 
Resistin (ng/mL) 8.47 ± 1.95 10.69 ± 2.11* 10.63 ± 2.15‡ 
CRP (µg/mL) 0.10 (0.05-0.37) 1.15 (0.49-4.51)* 0.55 (0.35-2.35)‡ 
MPO (ng/mL) 27.31 ± 10.69 45.76 ± 19.20* 35.14 ± 11.08† ‡ 
tPA (ng/mL) 2.25 (1.99-2.73) 3.17 (2.49-4.10)* 2.74 (2.24-3.32)† ‡ 
Values are mean ± SD, except for CRP and tPA which are median (IQR); CRP = C-reactive protein; DBP 423 
= diastolic blood pressure; IQR = interquartile range; MPO = myeloperoxidase; SBP = systolic blood 424 
 19 
pressure; SD = standard deviation; SOA = severely obese adolescents; tPA = tissue plasminogen 425 
activator. 426 
 427 
* Severely obese adolescents before weight loss versus normal-weight: P < .001 for age, weight, BMI, 428 
BMI z-score, waist circumference, leptin, and CRP; P = .002 for MPO; P = .003 for resistin; P = .039 for 429 
insulin; P = .044 for tPA. 430 
† Severely obese adolescents before versus after weight loss: P < .001 for age, height, weight, 431 
BMI, BMI z-score, and waist circumference; P = .014 for tPA; P = .016 for leptin; P = .020 for 432 
MPO.  433 
‡ Severely obese adolescents after weight loss versus normal-weight: P < .001 for weight, BMI, 434 
BMI z-score, and waist circumference; P = .002 for leptin; P = .004 for age, resistin, and CRP; P = 435 
.041 for insulin; P = .044 for MPO, and tPA.436 
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Table 2 Macrocirculation in normal-weight and severely obese adolescents before and after a 4-month weight loss program 
   SOA 
Variable Controls  Before  After 
Resting brachial artery diameter (mm) 3.13 ± 0.50  2.88 ± 0.55  3.05 ± 0.49† 
Resting brachial blood flow (ml min-1)  42.27 ± 25.65  65.30 ± 28.51*  62.63 ± 32.24‡ 
Resting brachial shear rate (s-1) 109.31 ± 47.11  232.05 ± 68.01*  193.49 ± 96.25† ‡ 
Peak brachial blood flow (ml min-1) 219.78 ± 80.22  278.17 ± 133.60  251.95 ± 98.27 
Peak brachial shear rate (s-1) 490.06 ± 122.00  744.32 ± 245.00*  570.98 ± 99.32† 
∆shear rate (s-1) 386.63 ± 139.59  511.24 ± 227.54  386.06 ± 87.72† 
FMD (%) 8.27 ± 3.27  7.53 ± 2.57  7.92 ± 3.30 
FMD/∆shear rate 0.024 ± 0.010  0.018 ± 0.008  0.021 ± 0.013 
NMD (%) 24.55 ± 8.04  18.21 ± 5.26*  20.42 ± 5.54 
Values are mean ± SD. FMD = flow-mediated dilation; NMD = nitrate-mediated dilation; SOA = severely obese adolescents. ∆shear 
rate means peak brachial shear rate minus resting brachial shear rate. 
 
* Severely obese adolescents before weight loss versus normal-weight: P < .001 for resting brachial shear rate; P = .005 for peak 
brachial shear rate; P = .011 for NMD; P = .017 for resting brachial blood flow.  
† Severely obese adolescents before versus after weight loss: P = .011 for resting brachial artery diameter, and peak brachial shear 
rate; P = .035 for resting brachial shear rate; P = .047 for ∆shear rate. 
‡ Severely obese adolescents after weight loss versus normal-weight: P = .004 for resting brachial shear rate; P = .046 for resting 
brachial blood flow. 
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Table 3 Microcirculation in normal-weight and severely obese adolescents before and after a 4-month weight loss program 
   SOA 
Variable Controls  Before  After 
Forearm resting CBF (PU) 8.69 (6.38-14.20)  6.66 (5.45-7.66)*  6.61 (4.87-7.55)‡ 
Forearm peak ACh iontophoresis CBF (PU) 63.68 (52.43-84.40)  70.96 (40.67-104.28)  60.37 (51.48-88.49) 
Forearm peak hyperthermia CBF (PU) 41.15 (35.40-70.51)  51.45 (33.89-74.01)  43.04 (35.36-51.81) 
Forearm peak SNP iontophoresis CBF (PU) 18.96 (10.98-27.04)  20.41 (9.11-38.29)  9.85 (7.52-21.08) 
Forearm peak CBF during NMD (PU) 21.54 (15.83-30.67)  13.29 (9.73-17.42)*  9.31 (7.21-12.79)† ‡ 
Values are median (IQR). ACh = acetylcholine; CBF = cutaneous blood flow; IQR = interquartile range; PU = perfusion units; SNP = 
sodium nitroprusside; SOA = severely obese adolescents. 
 
* Severely obese adolescents before weight loss versus normal-weight: P = .014 for forearm peak CBF during NMD; P = .019 for 
forearm resting CBF. 
† Severely obese adolescents before versus after weight loss: P = .015 for forearm peak CBF during NMD. 
‡ Severely obese adolescents after weight loss versus normal-weight: P < .001 for forearm peak CBF during NMD; P = .008 for 
forearm resting CBF. 
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Table 4 Associations of adiposity and biological measurements with vascular measures in normal-weight and severely obese 
adolescents before a 4-month weight loss program 
  
 
shear rate  
 
Brachial NMD  
Forearm resting 
CBF  
Forearm peak CBF 
during NMD 
Variable  r P  r P  r P  r P 
Adiposity measurements             
Weight  .343 NS  -.458 .006  -.348 .047  -.280 NS 
BMI  .372 .036  -.400 .019  -.393 .024  -.342 NS 
BMI Z-score  .337 NS  -.428 .012  -.365 .037  -.319 NS 
Waist circumference  .366 .043  -.473 .006  -.392 .026  -.266 NS 
Biological measurements             
Insulin  .014 NS  -.189 NS  -.171 NS  .203 NS 
Leptin  .343 NS  -.146 NS  -.447 .009  -.195 NS 
Resistin  .150 NS  -.110 NS  -.254 NS  -.528 .002 
CRP  .261 NS  -.162 NS  -.276 NS  -.329 NS 
MPO  .048 NS  -.132 NS  -.229 NS  -.381 .031 
tPA  .363 .045  -.286 NS  -.142 NS  -.079 NS 
CBF = cutaneous blood flow; CRP = C-reactive protein; DBP = diastolic blood pressure; MPO = myeloperoxidase; NMD = nitrate-
mediated dilation; tPA = tissue plasminogen activator. ∆shear rate means peak brachial shear rate minus resting brachial shear rate. 
